SuperworthAclarion ACON
- Market cap
- $5.6M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 66.4×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $83.8K
- +33% on a year ago
- Net margin
- n/m
- outside −100% to 100%
- Free cash flow yield
- n/m
- not a meaningful number
Aclarion trades at 66.4× sales. Its trailing earnings are negative, so it has no PE. Revenue was $83.8K over the last twelve months, up 33% on a year earlier.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $19.1K+5% | $13.8K−39% | $10.1K−60% | $11K−36% | $14.4K−24% | $10.2K−26% | $19K+88% | $19.3K+76% | $18.9K+32% | $18.5K+81% | $21.1K+11% | $25.2K+31% | |
| Cost of revenue | $19.6K+15% | $19.4K+12% | $19.5K+12% | $23.3K+21% | $21.3K+9% | $20.6K+6% | $23.5K+21% | $14.2K−39% | $14.6K−32% | $16.7K−19% | $17.4K−26% | $16.9K+19% |
| Gross profit | −$493 | −$5.6K | −$9.4K | −$12.3K+453% | −$6.9K+1305% | −$10.3K+84% | −$4.5K−52% | $5.1K | $4.4K | $1.8K | $3.8K | $8.3K+61% |
| R&D | $198.3K−32% | $220.7K+1% | $239K+17% | $202.1K−19% | $195.8K−1% | $251.8K+14% | $198.2K−17% | $270.4K+34% | $302K+54% | $263.1K+5% | $315.4K+59% | $297.1K+10% |
| SG&A | $963.4K−28% | $900K+24% | $1M+4% | $921.1K−20% | $1.1M+14% | $1.5M+72% | $1.3M+26% | $1.5M+60% | $1.5M+40% | $1.7M+12% | $2.7M+108% | $2.6M+78% |
| −$1.2M−29% | −$1.1M+20% | −$1.3M+8% | −$1.1M−19% | −$1.3M+12% | −$1.8M+60% | −$1.5M+17% | −$1.7M+53% | −$1.8M+41% | −$2M+10% | −$3M+100% | −$2.9M+67% | |
| Interest expense | $166.3K+7935% | $393.4K+18916% | $335.8K+24235% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Pre-tax income | −$998K−39% | −$1.3M+34% | −$2.4M+103% | −$1.2M−16% | −$1.4M+37% | −$2M+57% | −$2M−15% | −$1.6M+29% | −$1.7M+25% | −$1.9M−5% | −$2.9M+40% | −$2.7M+72% |
| $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net income | −$998K−39% | −$1.3M+34% | −$2.4M+103% | −$1.2M−16% | −$1.4M+37% | −$2M+57% | −$2M−15% | −$1.6M+29% | −$1.7M+25% | −$1.9M−5% | −$2.9M+40% | −$2.7M+72% |
| −$16914.15−44% | −$16487.95−6% | −$3.99−100% | −$1362.83−95% | −$1321.49−92% | −$1673.87−90% | −$9.32+134% | −$2.75−100% | −$2.93−100% | −$2.55−100% | −$1.34−86% | −$1.12−59% | |
| 59+9% | 77+42% | 602K+1097349% | 908+1486% | 1K+1670% | 1.2K+1486% | 219.4K−64% | 582.4K+64038% | 582.4K+55736% | 741.8K+60855% | 2.1M+871% | 2.5M+323% |
EPS, diluted: 10 periods, Q1 FY21 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q4 FY21 and Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY22: share-days: the 12-month average over 365 days less the 9-month over 273, the two on one basis (x16). Q4 FY23: a loss quarter: its basic count, share-days: the 12-month average over 365 days less the 9-month over 273, the two on one basis (x9047). Q4 FY24: a loss quarter: its basic count, share-days: the 12-month average over 366 days less the 9-month over 274, the two on one basis (x9047).
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Healthcare nearest Aclarion's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| ACONAclarion | $5.6M | n/m | n/a | 66.4× | +33% | n/m | |
| OXBROXBRIDGE RE HOLDINGS | $7.7M | 47.5× | 9.6× | 2.8× | +40% | 4.7% | |
| EDUCEducational Development | $8.7M | 5.4× | 11.3× | 0.4× | −32% | 8.6% | |
| GTIMGood Times Restaurants | $13.6M | 6.1× | 13.6× | 0.1× | −6% | 1.7% | |
| MDRRMedalist Diversified | $15.4M | 2.5× | 3.0× | 1.6× | −1% | 80.2% | |
| BCGBinah Capital | $18.2M | 6.7× | 20.8× | 0.1× | +8% | 2.2% | |
| VIPVulcan Infrastructure & Power | $19.6M | 17.9× | 24.4× | 0.4× | −14% | 1.0% | |
| MXCMexco Energy | $20.5M | 13.4× | 13.3× | 3.0× | −9% | 23.3% | |
| CKXCKX Lands | $21.5M | 7.4× | 32.6× | 31.0× | −17% | n/m | |
| MSGMMotorsport Games | $22.5M | 11.4× | 11.5× | 1.5× | +79% | 16.2% | |
| ATCHAtlasClear | $24M | 15.8× | 17.5× | 1.2× | +85% | 9.8% | |
| Peer median | $18.9M | 9.4× | 13.4× | 1.4× | −3% | 8.6% |
More on Aclarion
Each number over time
Its groups
About
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .